A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
Sarah GlewisMarliese AlexanderMuhammad N H KhabibAnnabelle BrennanSmaro LazarakisJennifer MartinJeanne TieSenthil LingaratnamMichael MichaelPublished in: British journal of cancer (2022)
The study is registered with PROSPERO, registration number CRD42020223768.